# Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib

> **NCT00332566** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 148 (actual)

## Conditions studied

- Hepatitis B
- Whole Cell Pertussis
- Tetanus
- Haemophilus Influenzae Type b
- Diphtheria

## Interventions

- **BIOLOGICAL:** DTPw-HBV/Hib Kft vaccine GSK323527A
- **BIOLOGICAL:** Tritanrix™-HepB/Hiberix™

## Key facts

- **NCT ID:** NCT00332566
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332566, "Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hib". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00332566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*